LON:VER - Vernalis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 5.51 -0.07 (-1.25 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseGBX 5.51
Today's RangeGBX 5.15 - GBX 5.26
52-Week RangeGBX 3.32 - GBX 26.25
Volume74,199 shs
Average Volume819,492 shs
Market Capitalization£17.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vernalis logoVernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.

Receive VER News and Ratings via Email

Sign-up to receive the latest news and ratings for VER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:VER
CUSIPN/A
Phone+44-118-9380000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-69.02%
Return on Equity-23.94%
Return on Assets-20.89%

Miscellaneous

EmployeesN/A
Outstanding Shares526,450,000
Market Cap£17.28

Vernalis (LON:VER) Frequently Asked Questions

What is Vernalis' stock symbol?

Vernalis trades on the London Stock Exchange (LON) under the ticker symbol "VER."

How were Vernalis' earnings last quarter?

Vernalis plc (LON:VER) issued its earnings results on Tuesday, September, 12th. The company reported ($4.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($4.50) by $0.40. The firm earned $20.79 million during the quarter. Vernalis had a negative net margin of 69.02% and a negative return on equity of 23.94%. View Vernalis' Earnings History.

What price target have analysts set for VER?

4 brokerages have issued 1 year price objectives for Vernalis' stock. Their predictions range from GBX 21 to GBX 31. On average, they anticipate Vernalis' share price to reach GBX 26.67 in the next year. This suggests a possible upside of 384.0% from the stock's current price. View Analyst Ratings for Vernalis.

What is the consensus analysts' recommendation for Vernalis?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vernalis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Vernalis' key competitors?

Who are Vernalis' key executives?

Vernalis' management team includes the folowing people:
  • Mr. Ian R. Garland, Chief Exec. Officer and Exec. Director (Age 52)
  • Mr. David MacKney, Chief Financial Officer and Exec. Director (Age 50)
  • Ms. Susan Wallcraft, Group Gen. Counsel & Company Sec.
  • Mr. Joseph Canny, VP of Marketing
  • Ms. Donna Radzik, Sr. VP of Pharmaceutical Quality Operations

Has Vernalis been receiving favorable news coverage?

News articles about VER stock have trended somewhat negative recently, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vernalis earned a media sentiment score of -0.17 on Accern's scale. They also gave media stories about the company an impact score of 48.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Vernalis?

Shares of VER and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Vernalis' stock price today?

One share of VER stock can currently be purchased for approximately GBX 5.51.

How big of a company is Vernalis?

Vernalis has a market capitalization of £17.28 million.

How can I contact Vernalis?

Vernalis' mailing address is 100 Berkshire Place, Wharfedale Road, WOKINGHAM, RG41 5RD, United Kingdom. The company can be reached via phone at +44-118-9380000.


MarketBeat Community Rating for Vernalis (LON VER)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  509
MarketBeat's community ratings are surveys of what our community members think about Vernalis and other stocks. Vote "Outperform" if you believe VER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.